18 F-FMiso) tumor binding as assessed by positron emisson topography (PET) was used to determine the responsiveness of each probe to modulation in tumor oxygenation levels in the SCCVII tumor model. Animals bearing the SCCVII tumor were injected with 64 Cu-ATSM or 18 F-FMiso followed by dynamic small animal PET imaging. Animals were imaged with both agents using different inspired oxygen mixtures (air, 10% oxygen, carbogen) which modulated tumor hypoxia as independently assessed by the hypoxia marker pimonidazole. The extent of hypoxia in the SCCVII tumor as monitored by the pimonidazole hypoxia marker was found to be in the following order: 10% oxygen > air > carbogen. Tumor uptake of 64 Cu-ATSM could not be changed if the tumor was oxygenated using carbogen inhalation 90 min post-injection suggesting irreversible cellular uptake of the 64 Cu-ATSM complex. A small but significant paradoxical increase in 64 Cu-ATSM tumor uptake was observed for animals breathing air or carbogen compared to 10% oxygen. There was a positive trend toward 18 F-FMiso tumor uptake as a function of changing hypoxia levels in agreement with the pimonidazole data.
Introduction
Hypoxic regions exist within tumors which may compromise the efficacy of radiotherapy and chemotherapy (1) (2) (3) (4) (5) (6) . Therefore a priori information of tumor hypoxia may be useful in the choice of treatment modalities. Non-invasive imaging methods that can provide spatially resolved qualitative/quantitative pO 2 information are desirable. Nuclear medicine techniques using hypoxia specific tracers (7, 8) and PET imaging using hypoxia specific tracers such as 18 F-labeled misonidazole (9) and Cu-ATSM are being evaluated for their capability in providing such information (10) (11) (12) (13) (14) .
Copper complexes of the thiosemicarbazine ligands have been recently identified as agents useful in nuclear medicine to assess hypoxia and blood flow (15) . Cu(II)-ATSM is a neutral lipophilic molecule, which is highly membrane permeable and can undergo reduction by cellular reducing equivalents and be converted to [Cu(I)-ATSM] - (15) , which becomes entrapped in cells by virtue of the unit negative charge. The reducing agents for Cu(II)-ATSM were variously identified as complex I of the mitochondrial electron transport chain, NADH cytochrome b5 reductase, NADPH cytochrome P-450 reductase, or intracellular thiols (15) . 64 Cu(II)-ATSM, unlike the 64 Cu(II)-PTSM analog, is di-alkylated and therefore more resistant to reduction except under significant hypoxic conditions (16) .
While several thiosemicarbazine ligands bind only Cu(II) but not Cu(I), the cuprous complex dissociates after reduction and released copper is bound to cellular macromolecules (17) . However, the Cu(I) complex of ATSM was suggested to be stable and remain intact even under strongly acidic conditions (16) and by virtue of its charge, it is trapped intracellularly when cells are hypoxic. Nitroimidazole agents undergo cellular reduction (7, 18, 19) , and in hypoxic conditions, are irreversibly converted to covalent adducts, ring fragmentation, and side-chain cleavage. However, in the case of Cu(II) 
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The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [ (20) . Additional immunohistochemical studies in the same model were carried out using the hypoxia marker pimonidazole.
Materials and methods

Animals and tumors.
Female C3H mice, produced by the National Cancer Institute Animal Production Area (Frederick, MD), were used for this study. The mice were 7-9 weeks of age at the time of experimentation and weighed between 20 and 30 g. Experiments were carried out under a protocol approved by the National Cancer Institute Animal Care and Use Committee, and were in compliance with the Guide for the Care and Use Of Laboratory Animal Resource, (1996) National Research Council. Tumors were grown in the mice by a subcutaneous (s.c.) injection of a single-cell suspension of 2x10 5 squamous cell carcinoma (SCCVII) cells on the right hind leg to a size of ~1.0 cm diameter 7-10 days after injection. Tumor volumes were determined prior to PET scanning, by measuring three orthogonal diameters using calipers. For all imaging studies ~1-cm diameter tumors were used. PET scanner. PET images were obtained with the ATLAS (Advanced Technology Laboratory Animal Scanner), a small animal PET scanner with an axial field-of-view (FOV) of 2 cm, a transverse FOV of 6.8 cm and an aperture of 8 cm (24) (25) (26) . Image data acquired with the ATLAS PET scanner were reconstructed using a three-dimensional reconstruction algorithm (27) .
Isotope preparation
PET scan experimental conditions. Each mouse was anesthetized with isoflurane (induction 2.0%; maintenance 1.5%) carried by air at 750 ml/min and delivered via a nosepiece. Once anesthesia was established further isoflurane was carried by either air (20.9% oxygen), carbogen (95% oxygen/5% CO 2 ), or 10% oxygen/90% nitrogen. In order to inject 64 Cu-ATSM or 18 F-FMiso intravenously (i.v.), a cannula was inserted into the tail vein (30-gauge ó" needle inserted into one end of a 60-cm length of PE10 tubing; IntraMedic Polyethylene, Becton Dickinson and Company, Sparks, MD). IV lines were filled with heparin (100 USP U/ml) prior to cannulation. A bladder catheter (PE10 tubing) was used to collect urine output and a rectal temperature probe (Fiso Fiber Optic Temperature Gauge, GenTek, Norcross, GA) was used to monitor core body temperature. Mice were immobilized in a specialized jig that secured the feet. This jig was inserted into a cylindrical Lucite chamber, fixed with a port for the attachment of thermostat-controlled, warm air circulator (Nikon Model ITC-32, Nikon Inc. Japan) in order to maintain the mouse's core temperature at 37˚C. The entire assembly was fixed to a computer-controlled motorized gantry capable of precisely moving the animal into the scanner. After a core temperature of 37˚C was established, PET image collection was started, and a 100-μl bolus of 64 Cu-ATSM (1-4 mCi) or 18 F-FMiso (200-400 μCi) in 0.9% saline was injected. Accurate measurements of the injected dose were recorded for each animal imaged.
The first series of studies were designed to test the hypothesis that 64 Cu-ATSM trapped in the tumor because of hypoxia might leak out when better oxygenation was provided to the tumor. For this experiment 3 mice were injected with 64 Cu-ATSM while breathing air. Dynamic images over the tumor were acquired for 180 min beginning just prior to the injection. At 90 min post-injection, the animals were switched to breathing carbogen. The second series of studies were designed to determine whether tumors took up more 64 Cu-ATSM when the animal was injected while breathing air compared to carbogen. Three tumor-bearing animals were injected with 64 Cu-ATSM while breathing air and dynamic imaging (beginning just prior to injection) was performed for 120 min (extended to 180 min in one animal). Another 3 mice were injected with 64 Cu-ATSM while breathing carbogen, and again dynamically imaged from just prior to injection to 120 min (extended to 180 min for 1 mouse). In addition, 64 Cu-ATSM tumor uptake studies were carried out on mice breathing 10% oxygen (used to increase tumor hypoxia). Similar studies were conducted using 18 F-FMiso.
To address the problem of mouse-to-mouse variations in tumor uptake, which might mask true changes in tumor uptake when air or carbogen was used, double injection studies were performed. Two mice were injected ( 64 Cu-ATSM) while breathing air and imaged dynamically for ~140 min. Seventy min into imaging, the mouse was switched to carbogen and injected again (15 min after beginning carbogen inhalation). Dynamic imaging was continuous throughout the entire 140 min. Two additional mice were studied in the same way, but began by breathing carbogen, were injected and 70 min later switched to air and injected again. This experiment permitted measuring how much uptake of ATSM occurs in the same tumor in the same mouse as a function of which gas was being administered (and therefore how well oxygenated the tumor was).
Integral blood input functions were determined by continuously collecting blood after injection with 64 Cu-ATSM. A catheter was placed in the jugular vein with PE10 tubing and connected to a Harvard pump. Blood was collected in the tubing for 30 min post-injection at a rate of 2 μl/min. After the collection, each end of the tubing was sealed, the tubing was placed in a counting tube, and the sample was counted. Total activity was corrected for decay, activity, and the weight of each respective tumor-bearing animal (air breathing, n=6; carbogen breathing, n=6).
Volumes of interest (VOI) were drawn semi-automatically over the tumors using a three dimensional region growing program from IDL (Research Systems Inc., Boulder, CO), based on a 40% (or in some cases other percentages, as described below) threshold of the maximum counts in a manually drawn crude region around the tumor. Values within the VOI were expressed as relative activity concentration per mCi injected per gram of body weight, unless otherwise specified. All data were corrected for radioactive decay.
Whole body 64 Cu-ATSM PET scan fusion with CT. Following some of the tumor scans with 64 Cu-ATSM, whole body PET scans were performed. Immediately after whole body PET scans, whole body CT scans (MicroCAT, CTI/ImTek, Inc., Knoxville, TN) were performed. The lucite fixture used for the PET scans was made to also fit the CT scanner, so that the animal could be scanned in the same orientation on both units.
Immunohistochemical assessment of hypoxia.
Immunohistochemical analysis of tumor hypoxia was determined using the hypoxia marker, pimonidazole (28) . Tumor-bearing mice were placed under conditions identical to the PET imaging studies for the hypoxia marker studies. Animals (n=3 per condition) were anesthetized with isoflurane and placed on a temperature-controlled water circulating pad adjusted to maintain a core body temperature of 37˚C. After equilibration, the isoflurane breathing mixture was carried by air (21% oxygen), carbogen (95% oxygen/5% CO 2 ), or 10% oxygen/ 90% nitrogen. After 15 min of breathing the various mixtures, pimonidazole was injected i.p. and the respective isoflurane/ oxygen mixtures were continued for 90 min. Following this exposure period, animals were euthanasized, tumors excised, and stored at -70˚C.
Tumor samples embedded with OCT compound (Sakura Finetek, Torrance, CA) were sectioned (6-μm sections) and placed on slides and processed with pimonidazole monoclonal antibody (200 μg/ml, Hydroxyprobe™, Chemicon International, Inc., Temecula, CA) (28) . Secondary anti-mouse IgG antibodies conjugated with Alexa Fluor 488 (2 μg/ml, Molecular Probes, Eugene, OR) were incubated for 1 h at room temperature. Sections were exposed to propidium iodide (PI, 50 μg/ml, Sigma, St. Louis, MO) for 2 min. Epifluorescent images were collected on an inverted microscope (Zeiss Axiovertvert 200, Carl Zeiss MicroImaging, Inc., Thornwood, NY) equipped with a mercury light source and CCD camera (Cooke Sensicam, Romulus MI). PI (which stains all nuclei red) and pimonidizole levels were quantified using ImagePro Plus (Mediacybernetics, Silver Spring MD). Images were taken and a histogram map of the grayscale intensities established. A threshold was established which prevented any grayscale intensities below the threshold from being included in the pimonidazole maps. The pimonidazole grayscale map was converted to a binary image for % area determination for each part of the section analyzed (4 per slide examined). Immediately after the pimonidazole image was taken, the microscope spectral filter was changed to detect the PI fluorescence (>600 nm). Again, as with the pimonidazole imaging, grayscale images were obtained and converted to binary maps to obtain the % PI area. The hypoxic fraction was determined by dividing the % area for the pimonidazole labeling divided by the % area of the PI staining. Data are expressed as the mean fluorescence value of four randomly selected regions within a tissue section (n=3 tumors). Data were analyzed using a 2-sided Student's t-test with unequal variances.
Results
To study the distribution of 64 Cu-ATSM in the tumor-bearing mouse, PET/CT studies were carried out in air breathing mice. 64 Cu-ATSM uptake was observed in the abdomen, tumorbearing leg, and head region of the animals. To better localize the uptake in the head, whole body CTs were conducted and the CT image was fused with the PET image (Fig. 1) . The 64 Cu-ATSM uptake in the head region did not appear to be in the brain, but localized to the nasal cavity and/or sinus. The reason for the uptake in this region is unknown.
Dynamic tumor uptake of 64 Cu-ATSM as a function of time is shown in Fig. 2 . This experiment permitted determination of whether uptake of 64 Cu-ATSM in a presumably hypoxic tumor washes out when the animal is made to breath carbogen. The ordinate has units proportional to average activity concentration (decay corrected) in the VOI (30% threshold) surrounding the tumor divided by the dose injected/g of whole body weight. Corrections were made for radioactive decay. As can be seen in the plot (each curve from a different mouse), there was essentially no change in 64 Cu-ATSM tumor uptake after carbogen breathing oxygenated the tumor. Fig. 2 demonstrated that 64 Cu-ATSM does not wash out with oxygenation by carbogen breathing.
64 Cu-ATSM tumor uptake was next determined when animals were injected while breathing air, compared to animals injected while breathing carbogen as shown in Fig. 3 . There was no statistically significant difference between tumor uptake (at 120 min) for tumors injected while breathing air or while breathing carbogen (0.92±0.14 versus 0.97±0.20, p=NS). However, there was considerable variation of 64 Cu-ATSM total tumor uptake for both air and carbogen breathing animals. This variability might influence the ability to detect air/carbogen differences. To reduce these variations we measured air versus carbogen 64 Cu-ATSM tumor uptake differences in the same tumor bearing animal. These studies utilized 2 separate injections of 64 Cu-ATSM in the same animal (60-70 min apart), one while breathing air, one while breathing carbogen (Fig. 4) . The second injection is corrected for the residual activity left from the first injection. This correction was performed in the following way: based on the data in Figs. 2 and 3 it was empirically determined that the shape of the tumor time activity curve could be very accurately described by A * (1. -exp(-B * time)) * exp(C * time), for times 10 min postinjection and later. Therefore, the data from 10 to 60 min following each of the first injections in Fig. 4 was fit to this function (solid curves in Fig. 4) for each mouse. This function was then used to subtract residual activity from injection 1 from the data of injection 2. The result of this subtraction is shown in the data from >60 min (i.e. the 2nd injection) in Fig. 4 , along with the corrected data (solid curve). Note that the initial activity at the time of second injection does not necessarily start at zero because the injection was not synchronized to the start of a new dynamic image. For the air ➝ carbogen studies ( Fig. 4A and B) in both mice carbogen 64 Cu-ATSM tumor uptake was greater than that observed when the animal was breathing air. For the reverse condition (carbogen ➝ air, Fig. 4C and D) , one animal showed greater 64 Cu-ATSM tumor uptake for carbogen (Fig. 4C) , while the second animal (Fig. 4D) showed greater tumor uptake while breathing air. Collectively, three of four animals gave a result opposite to that expected, i.e., 64 Cu-ATSM tumor uptake would be greater for animals breathing air (more hypoxia compared to when breathing carbogen). The arterial input function could change depending on which gas the mouse was breathing. Because of the challenges involved in estimating the arterial input function from images of an animal as small as a mouse, integrals of the arterial input functions were obtained by continuously collecting venous blood after injection with 64 Cu-ATSM. Blood was collected 30 min post-injection of 64 Cu-ATSM from tumor-bearing mice (matched to the mice in the imaging study for weight and tumor size). After the collection the entire sample was counted. Total activity was corrected for decay, activity, and the weight of each respective tumor-bearing animal (air breathing, n=6; carbogen breathing, n=6). Aside from any first pass extraction in the lung, this integral should equal the integral of arterial blood. The mean integral blood input, expressed as CPM/μCi/g for air and carbogen breathing animals, was 25.5±6.7 and 24.6±8.5, respectively (p=NS). Thus, no correction to the tumor 64 Cu-ATSM uptake was made.
Additional 64 Cu-ATSM tumor uptake studies were conducted for animals breathing 10% oxygen, which should make the tumor even more hypoxic. The mean tumor uptake of 64 Cu-ATSM when the animal was breathing 10% oxygen (n=5), 21% oxygen (air) (n=10), or carbogen (95% oxygen) (n=5) is shown in Fig. 5 . Where mice were studied with two injections, only the data from the first injection is used in Fig. 5 . Mean 64 Cu-ATSM tumor uptake in the tumors was 0.701±0.177 (SD), 1.02±0.28 and 1.21±0.36 for the 10%, 21%, and 95% oxygen mice, respectively. Both the 21% and 95% oxygen tumor uptake were significantly higher than the 10% oxygen uptake (p<0.04, (p<0.02, respectively). The 21% versus 95% oxygen uptakes were not significantly different.
The results using 64 Cu-ATSM indicated that altered tumor oxygenation did not affect 64 Cu-ATSM tumor uptake. Since this result was unexpected, we conducted another series of experiments using a different hypoxia marker 18 F-FMiso. Transaxial images of different mice injected 64 Cu-ATSM or 18 F-FMiso while breathing air are shown in Fig. 6 .
64 Cu-ATSM tumor uptake was more uniform than 18 F-FMiso, which exhibited hot regions and colder regions in the tumor. Hot regions were analyzed separately by 3D region growing taking all pixels with ≥90% of the maximum value within the tumor. When the 18 F-FMiso images were analyzed for binding as a function of time by considering either the hotspots (regions of high binding) or the entire tumor (Fig. 7) , the following observations were noted. First, the binding in the whole tumor reached a maximum within ~10 min after injection when the animals were breathing air or carbogen. For these studies animals received an initial injection of 64 Cu-ATSM while breathing air (A and B, n=2) and tumor uptake followed by microPET. After 90 min, the breathing mixture was switched to carbogen and 15 min after the carbogen breathing was initiated the animal was re-injected with a second injection of 64 Cu-ATSM followed by tumor uptake assessment by small animal PET imaging. C and D show the reverse sequence, carbogen ➝ air (n=2). Extrapolated data from the first injection were subtracted from the second injection. However, when the animal was breathing 10% oxygen the binding gradually increased until the end of the scan. Second, when the hot-spots were examined as a function of time they behaved very differently than the tumor as a whole. For the hot tumor regions a steady increase in uptake was noted in all the conditions of oxygen content in breathing gas tested. We examined whether the fraction of the tumor, which had high uptake differed depending on the oxygen concentration that was administered. The fractional volume of hot pixels versus oxygenation (Fig. 8) showed the binding to be in the following increasing order: 10% oxygen > air > carbogen (0.130±0.079, 0.0696±0.044 and 0.0378±0.04, respectively). However, none of these values were significantly different from any other.
Assessment of tumor oxygenation status was conducted using the hypoxia marker pimonidazole. Representative photomicrographs are shown in Fig. 9 of pimonidazole tumor cell binding (green) for animals breathing different oxygen mixtures. The hypoxia index (ratio of pimonidazole fluorescence divided by PI fluorescence) for air, carbogen, and 10% oxygen breathing was 18.7±7.1 (SD), 7.9±1.3 (p<0.11), and 36.0±7.0 (p<0.04), respectively.
Discussion
The initial hypothesis of this study proposed that tumor uptake of 64 Cu-ATSM would decrease if the tumor were oxygenated. This hypothesis was based on two assumptions. The first assumption was that tumor hypoxia can be decreased if a tumor-bearing animal is administered carbogen. The SCCVII tumor used in the present study is known to be quite hypoxic; however, carbogen breathing increases tumor oxygenation as measured by oxygen electrodes and functional OMRI studies in our laboratory (20) . Additionally, pimonidazole staining studies indicated that carbogen breathing increased oxygenation in the SCCVII tumor (Fig. 9) . The second assumption was that the cell permeable 64 Cu-ATSM complex would be reduced initially in hypoxic tumor cells to the stable cell-impermeable [Cu(I)-ATSM] -and that subsequent reoxygenation of hypoxic tumor cells should oxidize the complex back to 64 Cu-ATSM resulting in a decrease in tumor uptake (16) . Data presented in Fig. 2 show that we were unable to obtain data to support the hypothesis. The tumor uptake of 64 Cu-ATSM was clearly unchanged when the tumor-bearing animal was switched to carbogen breathing. [ 64 Cu(I)-ATSM] -is no longer stable as a complex and Cu(I) can be released and sequestered by cellular proteins in the intracellular milieu in agreement with the suggestion of Lewis et al (29) .
While 64 Cu-ATSM binds to tumor avidly, binding to the abdomen and nasal cavity was observed (Fig. 1) . 64 Cu-ATSM has recently been proposed to target tumor hypoxia for therapeutic radiation treatment (11, 30) . That 64 Cu-ATSM will bind to aerobic tissues is consistent with the data of Lewis et al, whose in vitro studies showed that the uptake of 64 Cu-ATSM in cells under aerobic conditions was approximately 40% (10) . Given the more effective cell killing by radiation under aerobic as opposed to hypoxic conditions, caution should be exercised in considering 64 Cu-ATSM for tumor treatment with regard to normal tissue toxicity.
There was considerable variability in 64 Cu-ATSM tumor uptake within each experimental group, despite careful attention to using animals of the same age, weight, tumor size, normalized 64 Cu-ATSM dose, and keeping experimental conditions the same. To minimize this variability, experiments were conducted where the same mouse was injected twice, once while breathing air and then switched to carbogen and injected again, and the reverse sequence (Fig. 4) . With appropriate corrections (subtracting the tumor uptake from the first injection and projecting the tumor uptake of the second injection), only 1 of 4 animals exhibited the expected oxygendependent 64 Cu-ATSM tumor uptake. Considering all of the studies conducted with 64 Cu-ATSM separately (Figs. 2-4 ), we were unable to demonstrate a consistent relationship between tumor oxygenation and 64 Cu-ATSM uptake. However, when we combined all air, carbogen and 10% oxygen studies (Fig. 5 ) a small but significant paradoxical increase in 64 Cu-ATSM uptake was found between 10% and 95% oxygen (p<0.02) and between 10% and 21% oxygen (p<0.04). In both cases 64 Cu-ATSM uptake increased with increasing tumor oxygen concentrations. This finding was unexpected and the reasons for the discrepancy between this study and published reports (29) with 64 Cu-ATSM are not clear. Lewis et al, reported an oxygen dependency of 61 Cu-ATSM tumor uptake of rat 9L gliosarcoma based on tumor oxygenation modulated by treatment with hydralazine (to induce more hypoxia) and breathing 100% oxygen (29) . Time-activity curves for 61 Cu-ATSM tumor uptake were conducted for 27 min post-injection. Hydralazine treatment resulted in slightly greater tumor uptake initially compared to animals breathing air; however, after 27 min this difference was diminished. For animals breathing 100% oxygen, the tumor uptake was 48% less than that observed in air breathing animals 27 min post-injection. In contrast, Yuan et al have shown that carbogen breathing, which oxygenated the rat FSA tumor as validated by the EF5 hypoxia probe, did not decrease 64 Cu-ATSM tumor uptake (compared to air breathing animals) (31) . Interestingly, in this study a direct comparison of tumor hypoxia was made comparing the hypoxia probe EF5 and 64 Cu-ATSM PET tumor binding for three rat tumor models. While a correlation with respect to hypoxia levels between EF5 and 64 Cu-ATSM was observed for two tumors, one tumor (FSA) showed no correlation at all, thus questioning the selectivity of 64 Cu-ATSM as a universal hypoxia marker (31) . Consistent with this study, Burgman et al, found that 64 Cu-ATSM uptake in vitro was cell line-dependent, suggesting that 64 Cu-ATSM may be disease site specific (32) . Interestingly, in this study one of the cell lines exhibited significant 64 Cu-ATSM uptake under aerobic conditions. Lastly, O'Donoghue et al, compared PET hypoxia imaging in two different rat tumor models for 64 Cu-ATSM and 18 F-FMiso and correlated the findings with oxygen electrode measurements (14) . 18 F-FMiso scans taken over the first 1-4 h post-injection were relatively constant and generally agreed with electrode measurements for both tumors studied. However, for the R-3327 tumor 64 Cu-ATSM uptake was unstable over this time period and only when 64 Cu-ATSM tumor uptake scans were evaluated 16-20 h post-injection did they agree with the 18 F-FMiso/electrode data. For the other tumor (FaDu) both early and late 64 Cu-ATSM scans were similar and in general in agreement with the 18 F-FMiso/ electrode data, demonstrating differences among tumor types with respect to 64 Cu-ATSM specificity for hypoxia imaging.
Additional studies were conducted using nitroimidazole binding ( 18 F-FMiso) in tumors in mice subjected to gases with different oxygen content. 18 F-FMiso tumor uptake was clearly different when compared to 64 Cu-ATSM uptake. 64 Cu-ATSM uptake was more uniform across the tumor; whereas, 18 F-FMiso uptake was more heterogeneous and spotty. While no statistical difference was demonstrated for the three oxygen breathing conditions, there was a trend for increased 18 F-FMiso tumor uptake (10% oxygen > air > carbogen).
As mentioned above, we have had experience in measuring oxygen levels in the SCCVII tumor for animals breathing air and carbogen using oxygen electrodes and have shown that carbogen markedly increases the oxygenation of SCCVII tumors (20) . However, for the present study we included an independent assessment of tumor hypoxia using pimonidazole. By using the various inspired oxygen concentrations, the extent of hypoxia varied in the SCCVII tumor as evidenced by the pimonidazole hypoxia index values (Fig. 9) . Carbogen breathing decreased hypoxia and 10% oxygen breathing clearly increased hypoxia in the SCCVII tumor, as expected.
In conclusion, with the SCCVII tumor model we were unable to demonstrate predictable changes in 64 Cu-ATSM tumor uptake when the oxygenation status of the tumor was modulated. Results using 18 F-FMiso were more positive with a trend toward greater uptake as hypoxia was increased in the tumor. The results of the present study question the use of 64 Cu-ATSM as a hypoxia specific marker; however, the avidity tumor uptake of 64 Cu-ATSM affords the opportunity of further research to discern the mechanism(s) of tumor binding.
